Form 4: Twist Bioscience Director Katryn Blake Increases Stake

Twist Bioscience Director Katryn Blake acquired 5,095 shares of common stock through an annual equity award, bringing her total beneficial ownership to 19,448 shares.

Summary

• Katryn Blake, a Director of Twist Bioscience Corp (TWST), acquired 5,095 shares of common stock.
• The transaction occurred on February 5, 2026.
• These shares were acquired at a price of $0, indicating they are part of an equity award.
• Following this transaction, Katryn Blake beneficially owns a total of 19,448 shares of Twist Bioscience Corp common stock.
• The acquired shares are subject to a vesting schedule, with 100% vesting upon the earlier of the one-year anniversary of the grant date or the date of the first annual meeting of stockholders following the grant date, provided she remains a Service Provider.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, as it represents a routine equity award to a director, increasing her stake and aligning her interests with shareholders, without indicating any adverse company-specific news.

Positives

• Director Katryn Blake's increased beneficial ownership to 19,448 shares aligns her interests more closely with shareholders.
• The grant of 5,095 shares as an annual equity award demonstrates ongoing compensation and retention of key board members.

Future Outlook

The 5,095 shares acquired by Director Katryn Blake are subject to a vesting schedule, with 100% vesting upon the earlier of the one-year anniversary of the grant date (February 5, 2027) or the date of the first annual meeting of stockholders following the grant date, contingent on her continued service as a Non-Employee Director.

Industry Context

StockSavvy.ai notes that routine equity awards to non-employee directors are a common practice across the biotechnology and life sciences sectors, serving to align director interests with long-term shareholder value and provide compensation for board service. This transaction is consistent with standard corporate governance practices for publicly traded companies like Twist Bioscience.

Related Party Transactions

• The acquisition of 5,095 shares by Director Katryn Blake from Twist Bioscience Corp constitutes a related party transaction, as it involves an insider receiving equity compensation from the issuer.

Stakeholder Impact

• Shareholders may view the increased beneficial ownership by a director as a positive signal of confidence in the company's future and improved alignment of interests.
• The company benefits from retaining experienced board members through equity compensation, which can incentivize long-term commitment.

Next Steps

• Vesting of the 5,095 shares upon the earlier of the one-year anniversary of the grant date (February 5, 2027) or the date of the first annual meeting of stockholders following the grant date.

Key Dates

Keywords

Twist Bioscience, TWST, Katryn Blake, Insider Transaction, Form 4, Equity Award, Director Compensation, Stock Ownership, Beneficial Ownership